Next Article in Journal
Preclinical Validation of a Novel Injection-Molded Swab for the Molecular Assay Detection of SARS-CoV-2
Previous Article in Journal
Preliminary Clinical Experience with a Novel Optical–Ultrasound Imaging Device on Various Skin Lesions
Article

Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers

1
Serviço de Patologia Clínica, Centro Hospitalar e Universitário de São João, 4200-319 Porto, Portugal
2
EPI Unit, Instituto de Saúde Pública, Universidade do Porto, 4200-135 Porto, Portugal
3
Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, 4200-135 Porto, Portugal
*
Author to whom correspondence should be addressed.
Academic Editor: Anna Baraniak
Diagnostics 2022, 12(1), 205; https://doi.org/10.3390/diagnostics12010205
Received: 7 December 2021 / Revised: 7 January 2022 / Accepted: 13 January 2022 / Published: 15 January 2022
(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
The humoral response through neutralizing antibodies (NAbs) is a key component of the immune response to COVID-19. However, the plaque reduction neutralization test (PRNT), the gold standard for determining NAbs, is technically demanding, time-consuming and requires BSL-3 conditions. Correlating the NAbs and total antibodies levels, assessed by generalized and automated serological tests, is crucial. Through a commercial surrogate virus neutralization test (sVNT), we aimed to evaluate the production of SARS-CoV-2 NAbs in a set of vaccinated healthcare workers and to correlate these NAbs with the SARS-CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. We found that 6 months after vaccination, only 74% maintain NAbs for the Wuhan strain/UK variant (V1) and 47% maintain NAbs for the South African and Brazil variants (V2). Through Spearman’s correlation, we found the following correlations between the percentage of inhibition of NAbs and the SARS-CoV-2 IgG II Quant (Abbott Laboratories, Chicago, IL, USA) and BioPlex 2200 SARS-CoV-2 IgG Panel (Bio-Rad, Hercules, CA, USA) immunoassays: rho = 0.87 (V1) and rho = 0.73 (V2) for anti-S1 assessed by Abbott assay; rho = 0.77 (V1) and rho = 0.72 (V2) for anti-S1, rho = 0.88 (V1) and rho = 0.82 (V2) for anti-RBD, and rho = 0.68 (V1) and rho = 0.60 (V2) for anti-S2 assessed by BioPlex assay (p < 0.001 for all). In conclusion, we found a strong correlation between this fast, user-friendly, mobile and bio-safe sVNT and the serological immunoassays. View Full-Text
Keywords: SARS-CoV-2; neutralizing antibodies; surrogate virus neutralization test; serological immunoassays; BNT162b2 vaccine SARS-CoV-2; neutralizing antibodies; surrogate virus neutralization test; serological immunoassays; BNT162b2 vaccine
Show Figures

Figure 1

MDPI and ACS Style

Ramos, A.; Cardoso, M.J.; Ribeiro, L.; Guimarães, J.T. Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers. Diagnostics 2022, 12, 205. https://doi.org/10.3390/diagnostics12010205

AMA Style

Ramos A, Cardoso MJ, Ribeiro L, Guimarães JT. Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers. Diagnostics. 2022; 12(1):205. https://doi.org/10.3390/diagnostics12010205

Chicago/Turabian Style

Ramos, Angélica, Maria J. Cardoso, Luís Ribeiro, and João T. Guimarães. 2022. "Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers" Diagnostics 12, no. 1: 205. https://doi.org/10.3390/diagnostics12010205

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop